Global drug companies Actavis and Teva both launched generic versions of Viagra immediately after its patent expired in several European countries last week.
The US Court of Appeals for the Federal Circuit concluded on June 18 that Novo Nordisk’s patent covering diabetes treatment repaglinide is invalid.
The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.
A majority of the US Supreme Court has ruled that the US Federal Trade Commission should be able to challenge so-called ‘pay-for-delay’ patent litigation settlements on antitrust grounds.
Generic drug-makers Teva Pharmaceutical and Sun Pharmaceutical have agreed to pay a combined $2.15 billion to settle a patent infringement case over Pfizer’s heartburn drug Protonix.
The US Supreme Court has ruled that isolated human DNA is not patent eligible and has struck down patents owned by biotech company Myriad, ending a long-running and controversial case.
India’s Intellectual Property Appellate Board has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.
Drug-maker Teva must wait until 2015 before selling generic versions of Shire’s Intuniv product, according to a patent settlement between the companies.
Japanese pharma company Takeda has sued generic drug-makers Impax and Sandoz for allegedly infringing a patent directed to its anti-heartburn drug Dexilant.
California-based biotechnology company Amgen has entered into a long-term partnership with Japanese pharmaceutical company Astellas Pharmas Inc to provide new medicines in Japan.